Innovations In Managing Patent Ductus Arteriosus

overview

Occurring frequently in preterm babies, patent ductus arteriosus (PDA) affects as many as 30% of babies weighing less than 1500 g at birth. The result can be life-threatening cardiac and pulmonary problems that drive the need for treatment. Some studies suggest that if left untreated, PDA can lead to serious complications in later life.

In this on-demand program, the expert faculty will review key epidemiologic and clinical issues involved with PDA; discuss the benefits and risks of surgical and medical therapies; compare drug therapies including indomethacin and intravenous ibuprofen; describe the role of prostaglandin inhibitors; and discuss pharmacologic options and pharmacoeconomic issues.

The convenient webcast format of this program provides an opportunity for neonatologists, pediatricians, nurses, pharmacists and other health care professionals involved in the care of preterm infants to update their knowledge and learn about promising new alternatives to treating PDA, based on their individual needs and schedules.

Join us for this free on-demand webcast specifically designed for clinicians treating patients with patent ductus arteriosus.

If you participated in the live webcast, you may not obtain CE credit for participation in this on-demand version.